Health
Rhythm Pharmaceuticals Announces IMCIVREE® (Setmelanotide) Granted Marketing Authorization by European Commission for the Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity
-- First therapy to be FDA-approved and EC-authorized for acquired hypothalamic obesity -- -- European Commission grants authorization in adults and children 4 years of age and above with acquired hypothalamic obesity due to hypothalamic injury or impairment -- BOSTON, May 01, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announ
About this update from Rhythm Pharmaceuticals, Inc.
[{"type":"image","alt":"Rhythm Pharmaceuticals, Inc.","displaySize":"","headline":null,"caption":"Rhythm Pharmaceuticals, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":105,"url":"https://media.zenfs.com/en/globenewswire.com/6c26dd8fa407cbf7aa92759a8a5fb54c"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/diOYkE69oi1YPSL0HU1OAw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE0Nw--/https://media.zenfs.com/en/globenewswire.com/6c26dd8fa407cbf7aa92759a8a5fb54c","width":300,"height":105}},"lazy":false},{"type":"text","content":"-- First therapy to be FDA-approved and EC-authorized for acquired hypothalamic obesity --","length":90,"tagName":"p"},{"type":"text","content":"-- European Commission grants authorization in adults and children 4 years of age and above with acquired hypothalamic obesity due to hypothalamic injury or impairment --","length":170,"tagName":"p"},{"type":"text","content":"BOSTON, May 01, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced the European Commission (EC) has expanded the marketing authorization for IMCIVREE® (setmelanotide) to include the treatment of obesity and control of hunger in adults and children 4 years of age and above with acquired hypothalamic obesity (HO) due to hypothalamic injury or impairment.","length":559,"tagName":"p"},{"type":"text","content":"“This EC authorization is an important step toward making the first new treatment option available to people living with acquired HO in Europe,” said David Meeker, M.D., Chairman, President and Chief Executive Officer of Rhythm Pharmaceuticals. “The hyperphagia and accelerated, sustained weight gain due to hypothalamic dysfunction resulting from direct injury or structural abnormality of the hypothalamus has a significant impact patients and families, who until now have had no approved treatment options. With this authorization in place, we look forward to working with local health authorities to support access for patients who may benefit throughout Europe.”","length":672,"tagName":"p"},{"type":"text","content":"Acquired HO is a rare neuroendocrine disease characterized by accelerated and sustained weight gain caused by hypoth...